School of Public Health, Anhui Medical University, Hefei 230032, China.
Biomolecules. 2023 Jan 18;13(2):195. doi: 10.3390/biom13020195.
Methyltransferase-like protein 7A (METTL7A), an RNA N6-methyladenosine (m6A) methyltransferase, has attracted much attention as it has been found to be closely associated with various types of tumorigenesis and progression. This study provides a comprehensive assessment of METTL7A from a pan-cancer perspective using multi-omics data. The gene ontology enrichment analysis of METTL7A-binding proteins revealed a close association with methylation and lipid metabolism. We then explored the expression of METTL7A in normal tissues, cell lines, different subtypes and cancers, and found that METTL7A was differentially expressed in various cancer species, tumor molecular subtypes and immune subtypes. Evaluation of the diagnostic and prognostic value of METTL7A in pan-cancer revealed that METTL7A had high accuracy in tumor prediction. Moreover, the low expression of METTL7A significantly correlated with the poor prognosis, including kidney renal clear cell carcinoma (KIRC), mesothelioma and sarcoma, indicating that METTL7A could be a potential biomarker for tumor diagnosis and prognosis. We focused on KIRC after pre-screening and analyzed its expression and prognostic value in various clinical subgroups. We found that METTL7A was significantly related to tumor stage, metastasis stage, pathologic stage, primary therapy outcome, histologic grade and gender, and that low METTL7A expression was associated with poorer outcomes. Finally, we analyzed the immune infiltration and co-expressed genes of METTL7A as well as the differentially expressed genes in the high and low expression groups. In conclusion, METTL7A is a better molecular marker for pan-cancer diagnosis and prognosis and has high potential as a diagnostic and prognostic biomarker for KIRC.
甲基转移酶样蛋白 7A（METTL7A）是一种 RNA N6-甲基腺苷（m6A）甲基转移酶，由于与多种类型的肿瘤发生和进展密切相关，因此备受关注。本研究从泛癌的角度，利用多组学数据对 METTL7A 进行了全面评估。METTL7A 结合蛋白的基因本体富集分析显示与甲基化和脂质代谢密切相关。然后，我们探讨了 METTL7A 在正常组织、细胞系、不同亚型和癌症中的表达，发现 METTL7A 在各种癌症类型、肿瘤分子亚型和免疫亚型中均有差异表达。评估 METTL7A 在泛癌中的诊断和预后价值发现，METTL7A 在肿瘤预测方面具有较高的准确性。此外，METTL7A 的低表达与预后不良显著相关，包括肾透明细胞癌（KIRC）、间皮瘤和肉瘤，表明 METTL7A 可能是肿瘤诊断和预后的潜在生物标志物。我们在预筛选后关注 KIRC，并分析了其在各种临床亚组中的表达和预后价值。我们发现 METTL7A 与肿瘤分期、转移分期、病理分期、原发治疗效果、组织学分级和性别显著相关，低 METTL7A 表达与预后不良相关。最后，我们分析了 METTL7A 的免疫浸润和共表达基因以及高低表达组之间的差异表达基因。总之，METTL7A 是一种更好的泛癌诊断和预后分子标志物，作为 KIRC 的诊断和预后生物标志物具有很高的潜力。
